Villejuif

• A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or M … Ended
  2024-513391-17-00 1 2025-05-27 Locally Advanced or Metastatic Solid Tumors
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21 non-small cell lung cancer (NSCLC)
• A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended
  2024-515410-41-00 9 2025-04-01 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T … Ended
  2023-505084-37-00 7 2025-03-17 Advanced Solid Tumors
• AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended
  2024-515391-12-00 1 2025-03-15 Advanced Solid Tumors with AKT1 E17K Mutation
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended
  2024-514356-33-00 7 2025-02-11 "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML),
• Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures Ended
  2023-503218-56-00 4 2025-01-30 Adult patients with a histologically confirmed TLS-positive advanced o
• A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or togethe … Ended
  2023-508998-85-00 1 2025-01-28 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• A Window of Opportunity (WoO) study evaluating pembrolizumab with or without olaparib in Tertiary Lymphoid Structures (TLS)-positive selecte … Ended
  2024-513469-38-00 4 2024-12-10 Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab … Ended
  2024-513697-22-00 5 2024-11-07 non-small-cell lung cancer
• Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular car … Ended
  2024-516408-40-00 9 2024-10-14 Non-resectable hepatocellular carcinoma (HCC)
• A safety study of PF-08046044/SGN-35C in adults with advanced cancers Ended
  2023-505813-26-00 1 2024-09-12 Lymphoma, Large B-Cell, Diffuse
• Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended
  2023-506866-30-00 4 2024-08-19 HER2 positive or HER2-low metastatic breast cancer
• GuARD: GR1014 cutaneous gel Against Radiation Dermatitis Ended
  2023-508728-36-00 4 2024-07-26 Radiation-induced dermatitis (radiodermatitis)
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended
  2023-509336-25-00 9 2024-06-12 Metastatic castration-resistant prostate cancer
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 4 2024-05-22 recurrent or persistent uterine serous carcinoma
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 7 2024-05-21 Patients with locally advanced or metastatic non-small cell lung cance
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 7 2024-04-29 Unresectable Locally Advanced or Metastatic Cancer
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)

Showing 769–792 of 961 trials